Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Janux Therapeutics Inc
(NQ:
JANX
)
56.08
+1.87 (+3.44%)
Streaming Delayed Price
Updated: 3:30 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Janux Therapeutics Inc
< Previous
1
2
3
Next >
Cracking The Code: Understanding Analyst Reviews For Janux Therapeutics
October 24, 2024
Via
Benzinga
Navigating 5 Analyst Ratings For Janux Therapeutics
September 06, 2024
Via
Benzinga
Analyst Expectations For Janux Therapeutics's Future
August 09, 2024
Via
Benzinga
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 07, 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
July 18, 2024
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins.
Via
Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
July 16, 2024
Via
Benzinga
The Latest Analyst Ratings For Janux Therapeutics
May 30, 2024
Via
Benzinga
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI
July 02, 2024
Although fraught with risk, these biotech exposures bring enormous upside potential.
Via
Talk Markets
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
May 31, 2024
Via
Benzinga
Analyst Ratings For Janux Therapeutics
May 13, 2024
Via
Benzinga
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Take the Money and Run: 3 Overbought Stocks to Sell ASAP
April 17, 2024
Although speculators were smart enough to jump on these ideas, they’re currently overbought stocks that may require trimming.
Via
InvestorPlace
A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts
April 16, 2024
Via
Benzinga
Why Janux Therapeutics Stock Is Crushing It This Week
April 12, 2024
Janux's silence about a potential acquisition deal could be golden.
Via
The Motley Fool
Forecasting The Future: 4 Analyst Projections For Janux Therapeutics
March 20, 2024
Via
Benzinga
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
April 16, 2024
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank?
Via
InvestorPlace
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 11, 2024
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.
Via
Benzinga
Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?
April 11, 2024
Janux Therapeutics may be up for sale amid interest from major pharmaceutical firms. With shares quadrupling this year and a successful equity offering, Janux is making waves in the industry. The...
Via
Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
April 11, 2024
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
April 11, 2024
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.
Via
Investor's Business Daily
Why Janux Therapeutics Stock Soared as the Market Sagged Today
April 10, 2024
One of the hotter biotech companies on the scene might be changing owners before long.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
April 04, 2024
Via
Benzinga
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst
March 20, 2024
Cantor Fitzgerald's coverage on Janux Therapeutics and its TRACTr/TRACir platform targeting diverse tumor antigens and cancer types. Analysts anticipate substantial growth potential driven by JANX007,...
Via
Benzinga
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023
March 15, 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
2 Stocks That Have More Than Tripled This Year: Are They Buys?
March 15, 2024
Don't jump on the bandwaggon too quickly.
Via
The Motley Fool
B of A Securities Maintains Buy Rating for Janux Therapeutics: Here's What You Need To Know
March 13, 2024
Via
Benzinga
5 Stocks That More Than Doubled In February
March 03, 2024
U.S. stocks rallied in February, with the S&P 500 and the Nasdaq Composite Index recording the best month in nearly a decade. Meanwhile, the Dow
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
March 02, 2024
The biotech tantalized investors with a very promising data update.
Via
The Motley Fool
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 12, 2024
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.
Via
Benzinga
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
February 28, 2024
The company reported in-line sales for the fourth quarter, but shares soared by double digits.
Via
Investor's Business Daily
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.